Advertisement

Journal of Molecular Neuroscience

, Volume 65, Issue 3, pp 367–376 | Cite as

Population-Based Analysis of Cluster Headache-Associated Genetic Polymorphisms

  • Martha-Spyridoula Katsarou
  • Maria Papasavva
  • Rozana Latsi
  • Ioanna Toliza
  • Alfrent-Pantelis Gkaros
  • Stylianos Papakonstantinou
  • Stylianos Gatzonis
  • Dimos-Dimitrios Mitsikostas
  • Leda Kovatsi
  • Boris N. Isotov
  • Aristides M. Tsatsakis
  • Nikolaos Drakoulis
Article
  • 84 Downloads

Abstract

Cluster headache is a disorder with increased hereditary risk. Associations between cluster headache and polymorphism rs2653349 of the HCRTR2 gene have been demonstrated. The less common allele (A) seems to reduce disease susceptibility. The polymorphism rs5443 of the GNB3 gene positively influences triptan treatment response. Carriers of the mutated T allele are more likely to respond positively compared to C:C homozygotes, when treated with triptans. DNA was extracted from buccal swabs obtained from 636 non-related Southeastern European Caucasian individuals and was analyzed by real-time PCR. Gene distribution for the rs2653349 was G:G = 79.1%, G:A = 19.2%, and A:A = 1.7%. The frequency of the wild-type G allele was 88.7%. The frequencies for rs5443 were C:C = 44.0%, C:T = 42.6%, and T:T = 13.4%. The frequency of the wild-type C allele was 65.3%. The frequency distribution of rs2653349 in the Southeastern European Caucasian population differs significantly when compared with other European and East Asian populations, and the frequency distribution of rs5443 showed a statistically significant difference between Southeastern European Caucasian and African, South Asian, and East Asian populations. For rs2653349, a marginal statistically significant difference between genders was found (p = 0.080) for A:A versus G:G and G:A genotypes (OR = 2.78), indicating a higher representation of male homozygotes for the protective mutant A:A allele than female. No statistically significant difference was observed between genders for rs5443. Cluster headache pathophysiology and pharmacotherapy response may be affected by genetic factors, indicating the significant role of genotyping in the overall treatment effectiveness of cluster headaches.

Keywords

GNB3 HCRTR2 Cluster headache therapy Southeastern European Caucasians Pharmacogenomics 

Abbreviations

CH

Cluster headache

IHS

International Headache Society

TACs

Trigeminal autonomic cephalalgias

SNP

Single-nucleotide polymorphism

HCRTR2

Hypocretin receptor type 2

5-HT

5-hydroxytryptamine

GNB3

G protein beta-3 subunit

SEC

Southeastern European Caucasians

OR

Odds ratio

CI

Confidence intervals

HWE

Hardy–Weinberg equilibrium

PET

Positron-emission tomography

CGRP

Calcitonin-gene related peptide

IL-2

Interleukin-2

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. Ashkenazi A, Schwedt T (2011) Cluster headache-acute and prophylactic therapy. Headache J Head Face Pain 51(2):272–286.  https://doi.org/10.1111/j.1526-4610.2010.01830.x CrossRefGoogle Scholar
  2. Costa M, Squassina A, Piras IS, Pisanu C, Congiu D, Niola P, Angius A et al (2015) Preliminary transcriptome analysis in lymphoblasts from cluster headache and bipolar disorder patients implicates dysregulation of circadian and serotonergic genes. J Mol Neurosci 56(3):688–695.  https://doi.org/10.1007/s12031-015-0567-9 CrossRefPubMedGoogle Scholar
  3. Dardiotis E, Siokas V, Sokratous M, Tsouris Z, Michalopoulou A, Andravizou A, Dastamani M et al (2018) Genetic polymorphisms in amyotrophic lateral sclerosis: evidence for implication in detoxification pathways of environmental toxicants. Environ Int 116:122–135.  https://doi.org/10.1016/j.envint.2018.04.008 CrossRefPubMedGoogle Scholar
  4. Dardiotis E, Xiromerisiou G, Hadjichristodoulou C, Tsatsakis AM, Wilks MF, Hadjigeorgiou GM (2013) The interplay between environmental and genetic factors in Parkinson’s disease susceptibility: the evidence for pesticides. Toxicology 307:17–23.  https://doi.org/10.1016/j.tox.2012.12.016 CrossRefPubMedGoogle Scholar
  5. Empl M, Förderreuther S, Schwarz M, Müller N, Straube A (2003) Soluble Interleukin-2 receptors increase during the active periods in cluster headache. Headache J Head Face Pain 43(1):63–68.  https://doi.org/10.1046/j.1526-4610.2003.03011.x. CrossRefGoogle Scholar
  6. Goadsby PJ (2002) Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurol 1(4):251–257.  https://doi.org/10.1016/s1474-4422(02)00104-7 CrossRefPubMedGoogle Scholar
  7. Haghparast A, Fatahi Z, Arezoomandan R, Karimi S, Taslimi Z, Zarrabian S (2017) Functional roles of orexin/hypocretin receptors in reward circuit. Prog Brain Res 235:139–154.  https://doi.org/10.1016/bs.pbr.2017.08.005 CrossRefPubMedGoogle Scholar
  8. Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1–211.  https://doi.org/10.1177/0333102417738202 CrossRefGoogle Scholar
  9. Katsarou M-S, Latsi R, Papasavva M, Demertzis N, Kalogridis T, Tsatsakis AM, Spandidos DA, Drakoulis N (2016) Population-based analysis of the frequency of HFE gene polymorphisms: correlation with the susceptibility to develop hereditary hemochromatosis. Mol Med Rep 14(1):630–636.  https://doi.org/10.3892/mmr.2016.5317
  10. Katsarou M-S, Karakonstantis K, Demertzis N, Vourakis E, Skarpathioti A, Nosyrev AE, Tsatsakis A, Kalogridis T, Drakoulis N (2017) Effect of single-nucleotide polymorphisms in ADH1B, ADH4, ADH1C, OPRM1, DRD2, BDNF, and ALDH2 genes on alcohol dependence in a Caucasian population. Pharmacol Res Perspect 5(4):e00326.  https://doi.org/10.1002/prp2.326
  11. Klenke S, Kussmann M, Siffert W (2011) The GNB3 C825T polymorphism as a pharmacogenetic marker in the treatment of hypertension, obesity, and depression. Pharmacogenet Genomics 21(9):594–606.  https://doi.org/10.1097/FPC.0b013e3283491153 CrossRefPubMedGoogle Scholar
  12. Law S, Derry S, Moore RA (2013). Triptans for acute cluster headache. Cochrane Database Syst Rev (7):CD008042.  https://doi.org/10.1002/14651858.CD008042.pub3
  13. Leone M, Lucini V, D’Amico D, Grazzi L, Moschiano F, Fraschini F, Bussone G (1998) Abnormal 24-hour urinary excretory pattern of 6-sulphatoxymelatonin in both phases of cluster headache. Cephalalgia 18(10):664–667.  https://doi.org/10.1046/j.1468-2982.1998.1810664.x CrossRefPubMedGoogle Scholar
  14. Lucini V, Fraschini F, Leone M, D’amico D, Moschiano F, Maltempo C, Bussone G (1995) Twenty-four-hour melatonin and cortisol plasma levels in relation to timing of cluster headache. Cephalalgia 15(3):224–229.  https://doi.org/10.1046/j.1468-2982.1995.015003224.x CrossRefPubMedGoogle Scholar
  15. Matharu M (2010) Cluster headache. BMJ Clin Evid 2010:1212PubMedPubMedCentralGoogle Scholar
  16. Nasman J, Bart G, Larsson K, Louhivuori L, Peltonen H, Akerman KEO (2006) The orexin OX1 receptor regulates Ca2+ entry via diacylglycerol-activated channels in differentiated neuroblastoma cells. J Neurosci 26(42):10658–10666.  https://doi.org/10.1523/JNEUROSCI.2609-06.2006 CrossRefPubMedGoogle Scholar
  17. Neeb L, Anders L, Euskirchen P, Hoffmann J, Israel H, Reuter U (2015) Corticosteroids alter CGRP and melatonin release in cluster headache episodes. Cephalalgia 35(4):317–326.  https://doi.org/10.1177/0333102414539057 CrossRefPubMedGoogle Scholar
  18. Pinessi L, Rainero I, Rivoiro C, Rubino E, Gallone S (2005) Genetics of cluster headache: an update. J Headache Pain 6(4):234–236.  https://doi.org/10.1007/s10194-005-0194-x CrossRefPubMedPubMedCentralGoogle Scholar
  19. Rainero I, Rubino E, Valfrè W, Gallone S, Martino P, Zampella E, Pinessi L (2007) Association between the G1246A polymorphism of the hypocretin receptor 2 gene and cluster headache: a meta-analysis. J Headache Pain 8(3):152–156.  https://doi.org/10.1007/s10194-007-0383-x CrossRefPubMedPubMedCentralGoogle Scholar
  20. Schürks M, Kurth T, Stude P, Rimmbach C, de Jesus J, Jonjic M, Rosskopf D (2007) G protein β3 polymorphism and Triptan response in cluster headache. Clin Pharmacol Ther 82(4):396–401.  https://doi.org/10.1038/sj.clpt.6100159 CrossRefPubMedGoogle Scholar
  21. Steinberg A, Sjöstrand C, Sominanda A, Fogdell-Hahn A, Nilsson Remahl AIM (2011) Interleukin-2 gene expression in different phases of episodic cluster headache—a pilot study. Acta Neurol Scand 124(2):130–134.  https://doi.org/10.1111/j.1600-0404.2010.01434.x CrossRefPubMedGoogle Scholar
  22. Thompson MD, Xhaard H, Sakurai T, Rainero I, Kukkonen JP (2014) OX(1) and OX(2) orexin/hypocretin receptor pharmacogenetics. Front Neurosci 8:57.  https://doi.org/10.3389/fnins.2014.00057 PubMedPubMedCentralCrossRefGoogle Scholar
  23. Tsatsakis AM, Androutsopoulos VP, Zafiropoulos A, Babatsikou F, Alegakis T, Dialyna I, Tzatzarakis M, Koutis C (2011) Associations of xenobiotic-metabolizing enzyme genotypes PON1Q192R, PON1L55M and CYP1A1*2A MspI with pathological symptoms of a rural population in South Greece. Xenobiotica 41(10):914–925.  https://doi.org/10.3109/00498254.2011.590545
  24. Tsujino N, Sakurai T (2009) Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev 61(2):162–176.  https://doi.org/10.1124/pr.109.001321 CrossRefPubMedGoogle Scholar
  25. Waldenlind E, Gustafsson SA, Ekbom K, Wetterberg L (1987) Circadian secretion of cortisol and melatonin in cluster headache during active cluster periods and remission. J Neurol Neurosurg Psychiatry 50(2):207–213.  https://doi.org/10.1136/jnnp.50.2.207 CrossRefPubMedPubMedCentralGoogle Scholar
  26. Weaver-Agostoni J (2013) Cluster headache. Am Fam Physician 88(2):122–128PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Martha-Spyridoula Katsarou
    • 1
  • Maria Papasavva
    • 1
  • Rozana Latsi
    • 1
  • Ioanna Toliza
    • 1
  • Alfrent-Pantelis Gkaros
    • 2
  • Stylianos Papakonstantinou
    • 1
  • Stylianos Gatzonis
    • 3
  • Dimos-Dimitrios Mitsikostas
    • 4
  • Leda Kovatsi
    • 5
  • Boris N. Isotov
    • 6
  • Aristides M. Tsatsakis
    • 7
  • Nikolaos Drakoulis
    • 1
  1. 1.Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health SciencesNational and Kapodistrian University of AthensAthensGreece
  2. 2.Department of Statistics and Insurance Science, School of Finance and StatisticsUniversity of PiraeusPiraeusGreece
  3. 3.A’ Neurosurgical Clinic, Evangelismos Hospital, School of MedicineNational and Kapodistrian University of AthensAthensGreece
  4. 4.First Department of Neurology, Eginition Hospital, School of MedicineNational and Kapodistrian University of AthensAthensGreece
  5. 5.Laboratory of Forensic Medicine and Toxicology, School of MedicineAristotle University of ThessalonikiThessalonikiGreece
  6. 6.Department of Analytical Toxicology, Pharmaceutical Chemistry and PharmacognosySechenov UniversityMoscowRussia
  7. 7.Laboratory of Toxicology, Medical SchoolUniversity of CreteCreteGreece

Personalised recommendations